Lysoway Therapeutics Inc. has synthesized mucolipin-1 (MCOLN1; TRPML1) activators reported to be useful for the treatment of age-related macular degeneration, aging, Alzheimer’s disease, cancer, Charcot-Marie-Tooth disease, cystic fibrosis, muscular dystrophy and type C Niemann-Pick disease.
Scientists at Meta Pharmaceutical (HK) Ltd. and Shenzhen Moyuan Pharmaceuticals Co. Ltd. have disclosed lactate dehydrogenase A (LDHA) inhibitors reported to be useful for the treatment of cancer, allergy, among others.
Westlake Pharmaceutical (Hangzhou) Co. Ltd. has prepared and tested new 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer.
Memorial Sloan Kettering Cancer Center has patented eponemycin analogues acting as proteasome inhibitors and thus potentially useful for the treatment of cancer.
Work at Hepaitech (Beijing) Biopharma Technology Co. Ltd. has led to the identification of Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of anemia, fungal infections, HIV infections, renal disorders, liver diseases, psoriasis, pruritus and urticaria, among others.
A Nettargets Inc. patent describes histone-lysine N-methyltransferase SETDB1 (KIAA0067, KMT1E) inhibitors reported to be useful for the treatment of cancer.
Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.
RSS